Please assess the completion status of the following clinical trial:

Trial Title: Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, all races and ethnicities are eligible~* Age equal to or greater than 18 years of age~* All subjects should have a pathological/histological diagnosis of colorectal cancer.~* Clinical diagnosis of stage I, II, III or IV colon cancer or stage I, II, III or IV rectal cancer; cancer may be primary including a secondary primary~* Candidate for elective surgery(for removal of primary) or endoscopic biopsy~* ECOG Performance status of 0 - 2~* Adequate renal, liver, and bone marrow function~* Hb: (adequate for surgical intervention, with transfusion if necessary)~* WBC: (normal range)~* Platelets: (180K/cmm)~* LFTs: Normal bilirubin (\< 2.0mg/dL), AST/ALT (2xULN)~* Renal function: normal creatinine~* Subjects must have signed informed consent~* Female subjects must either not be of child-bearing potential or must have a negative urine pregnancy test within 7 days of beginning the drug or placebo treatment. Subjects are considered not of child-bearing potential if they are surgically sterile or they are postmenopausal for greater than 12 months.~Exclusion Criteria:~* Previously diagnosed with diabetes mellitus Type 1 or Type 2.~* Currently taking biguanides, sulfonylurea drugs, thiazolidinediones, insulin, or mTOR inhibitors or having taken any of these medications during the 12 weeks prior to study participation.~* Currently taking any non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin and unable to stop such medications due to a present medical condition.~* Clinical symptoms of gastrointestinal obstruction or bleeding and consideration for immediate surgery or immediate neoadjuvant chemoradiation.~* Familial Adenomatous Polyposis (FAP), hereditary non-polyposis colorectal cancer (HNPCC), Putz-Jeghers disease, ulcerative colitis, or Crohn's disease.~* Pregnant or lactating.~* History of lactic or other metabolic acidosis.~* Known hypersensitivity to Metformin.~* Uncontrolled infectious disease.~* History of Positivity for human immunodeficiency virus (HIV).~* History of congestive heart failure requiring pharmacologic treatment.~* History of excessive alcohol abuse, defined by a habitual intake of more than three drinks daily.~* Previous or concurrent malignancies, except non-melanoma skin cancers, unless curatively treated and with no evidence of recurrence for \> 5 years, with the exception of prior CRC which has been treated and the patient has been in remission and the current primary tumor is a second CRC.~* Unable to swallow and retain oral medication.~* Mal-absorption syndrome, disease affecting gastrointestinal function, or previous resection of the stomach or small bowel.~* Current use of medications for weight loss.~* Currently taking cimetidine, thiazide diuretics or cephalexin. If a patient needs some of these agents, alternative agents should be substituted.~* If the physician feels that the candidate is not suitable for the study, he/she will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo 2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
- Metformin (Type: ACTIVE_COMPARATOR): Metformin 850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days

Based on this trial design, predict the completion outcome and termination type (if applicable).